On June 20, 2016, the full Federal Circuit denied Mylan’s petitions for rehearing en banc in Acorda Therapeutics Inc. v. Mylan Pharms. Inc., 817 F.3d 755 (Fed. Cir. 2016), leaving intact the panel’s decision affirming two...more
6/23/2016
/ Abbreviated New Drug Application (ANDA) ,
BPCIA ,
Commercial Marketing ,
Corporate Counsel ,
Forum Selection ,
Generic Drugs ,
Manufacturers ,
Mylan Pharmaceuticals ,
Out-of-State Companies ,
Patent Litigation ,
Patent Validity ,
Patents ,
Personal Jurisdiction
Since the Supreme Court’s decision in Daimler AG v. Bauman, 134 S.Ct. 746 (2014)—effectively limiting the reach of general jurisdiction to defendant’s “home” states of incorporation or principal place of business—generic drug...more
Under 35 U.S.C. § 271(e), filing an Abbreviated Biologics License Application (aBLA)—like filing an Abbreviated New Drug Application (ANDA)— can be an act of patent infringement resulting in ‘artificial’ injury to a patentee....more
10/5/2015
/ Abbreviated New Drug Application (ANDA) ,
aBLA ,
Biologics ,
BPCIA ,
Consent ,
DaimlerAG ,
DaimlerChrysler v Bauman ,
General Jurisdiction ,
Interlocutory Appeals ,
Motion to Dismiss ,
Patent Infringement ,
Patents ,
Personal Jurisdiction ,
Pharmaceutical Industry ,
SCOTUS ,
Specific Jurisdiction
An emerging issue in Hatch-Waxman litigation – and potentially under the Biologics Price Competition and Innovation Act (BPCIA) – is the impact of the Supreme Court’s decision in Daimler AG v. Bauman, 134 S. Ct.746 (2014), on...more